| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7daafa4ae4a63958ce41a28f11eaadf5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2021-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9aa91402de5df4c92868c0ac1348b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36ec5ff17c3c892f9d35d7305a835b38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56aa94da39b1028182761d60be01ff4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_117962cf50db043ecffcbb5810791d20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfd97239214ade4a7914cd04fc0ef6e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_622b2a579669929fc6ca492a1783c8b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a8d8f79103ccc2939561ee7a2558f9b |
| publicationDate |
2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210114904-A |
| titleOfInvention |
Pharmaceutical composition for treating cancers comprising guide rna and endonuclease |
| abstract |
The present invention relates to a pharmaceutical composition for treating cancer comprising crRNA and endonuclease as active ingredients. The present invention can be tailored to the needs of a patient or cell type by specifically treating cancer cells based on the specific binding properties of DNA and RNA. The nuclease activity of the CRISPR PLUS system according to the present invention can be activated by binding of crRNA to a gene specifically present in cancer cells. Therefore, the cancer treatment effect of the present invention is more specific than other anticancer agents currently developed. |
| priorityDate |
2018-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |